Hematologic Cancer
34
11
13
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.9%
1 terminated out of 34 trials
88.9%
+2.4% vs benchmark
3%
1 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (34)
Avera Cancer Sequencing and Analytics Protocol (ASAP)
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Early Detection of Complications During Immunotherapy for Haematological Malignancy
Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy
The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignance Patients With Extramedullary Infiltrating
Discontinuation Study
The Florida ASCENT Study
Coverage and Cost of Care Links- Telehealth
Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
Precision Physical Exercise for Personalized Onco-Hematology.
SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)
Improving Comprehensive Care of Cancer Patients
Hypnosis: a Path to Appeasement
Symptom Management for YA Cancer Survivors
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Improving Patient Experience: BMBA
Intervention for Fatigue in HCT Recipients
Coverage and Cost-of-Care (CC) Links- Financial Navigation Program
Photobiomodulation for Oral Mucositis and Functional Impairments During Hematopoietic Stem Cell Transplantation
Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT